Working together in cardiovascular prevention: The common mission of the European Heart Journal and the European Journal of Preventive Cardiology

European Journal of Preventive Cardiology

Volumn 19, Issue 6, 2012, Pages 1217-1226

  Lüscher, Thomas F ^a   Landmesser, Ulf ^a   Ruschitzka, Frank ^a   Grobbee, Diederick E ^b  

^a University Hospital of Zurich   (Switzerland)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CHOLESTEROL; DIURETIC AGENT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; RENIN INHIBITOR; SMALLPOX VACCINE;

ATHEROSCLEROSIS; BODY FAT; CARDIOLOGY; CHOLESTEROL METABOLISM; DIABETES MELLITUS; EXERCISE; HUMAN; INFLAMMATION; MEDICAL DEVICE; METABOLIC DISORDER; NEPHRITIS; NONHUMAN; OBESITY; PRACTICE GUIDELINE; PREVENTIVE MEDICINE; PRIORITY JOURNAL; PUBLICATION; REVIEW; SMALLPOX; SPORT;

CARDIOVASCULAR DISEASES; COOPERATIVE BEHAVIOR; EDITORIAL POLICIES; EVIDENCE-BASED MEDICINE; FORECASTING; HISTORY, 19TH CENTURY; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; INFORMATION DISSEMINATION; PERIODICALS AS TOPIC; PRACTICE GUIDELINES AS TOPIC; PRIMARY PREVENTION; PROGNOSIS; RISK ASSESSMENT; RISK FACTORS; RISK REDUCTION BEHAVIOR; TIME FACTORS;

EID: 84873653398     PISSN: 20474873     EISSN: None     Source Type: Journal    
DOI: 10.1177/2047487312467876     Document Type: Review

References (81)

1. Virchow R. Gesammelte Abhandlungen zur wissenschaftlichen Medizin. Frankfurt: AM Meidinger, 1856. 478, fn.
2. Virchow R. Erinnerungsblatter. Arch Path Anat Physiol. 1852 ; 4: 541-548
3. Anitschkow N, Chalatow S. Ueber experimentelle Cholester-insteatose und ihre Bedeutung fuer die Entstehung einiger pathologischer Prozesse. Zentrbl Allg Pathol Pathol Anat. 1913 ; 24: 1-9
4. de Langen CD. Cholesterol metabolism and racial pathology [in Dutch]. Geneesk Tijdschr Nederl Indië. 1916 ; 56: 1-34
5. Kromhout D, Menotti A, Kesteloot H, et al. Prevention of coronary heart disease by diet and lifestyle: evidence from prospective cross-cultural, cohort, and intervention studies. Circulation. 2002 ; 105: 893-898
6. Dawber TR, Meadors GF, Moore FE. National Heart Institute, National Institutes of Health, Public Health Service, Federal Security Agency, Washington, DC, Epidemiological approaches to heart disease: the Framingham study presented at a joint session of the epidemiology, health officers, medical care, and statistics sections of the American Public Health Association, at the seventy-eighth annual meeting in St. Louis, Mo, 1950. Am J Public Health Nations Health. 1951 ; 41: 279-281
7. Lerner DJ, Kannel W. Patterns of coronary heart disease morbidity and mortality in the sexes: a 26-year follow-up of the Framingham population. Am Heart J. 1986 ; 111: 383-390
8. Haeusler G. Potential future developments in the field of antihypertensive drugs. Eur Heart J. 1987 ; 8: 135-142
9. Mancia G, de Backer G, Dominiczak A, et al. 2007 guidelines for the management of hypertension. Eur Heart J. 2007 ; 28: 1462-1538
10. Redon J, Olsen MH, Cooper RS, et al. Stroke mortality and trends from 1990 to 2006 in 39 countries from Europe and Central Asia: implications for control of high blood pressure. Eur Heart J. 2011 ; 32: 1424-1431
11. ESC Committee for Practice Guidelines (CPG) 2008-2010 and 2010-2012 Committees. Eur Heart J. 2011 ; 32: 1769-1818
12. Tokgozoglu L, Bruckert E. Implementation, target population, compliance and barriers to risk guided therapy. Eur J Prev Cardiol. 2012 ; 19: 37-41
13. Joseph J, Svartberg J, Njølstad I, et al. Change in cardiovascular risk factors in relation to diabetes status: the Tromsø study. Eur J Prev Cardiol. 2012 ; 19: 551-557
14. Julian DG. Birth and growth of the European Society of Cardiology. Eur Heart J. 1980 ; 1: 5-7
15. Lüscher TF, Gersh B, Brugada J, et al. The European Heart Journal goes global - the road ahead of the editorial tam 2009-2011. Eur Heart J. 2009 ; 30: 1-5
16. Lüscher TF, Dedecke S, Gersh B, et al. Happy Birthday European Heart Journal - in 30 years from Cinderella to center stage. Eur Heart J. 2011 ; 31: 1945-1950
17. Lüscher TF, Gersh B, Hindricks G, et al. The European Heart Journal on the move - can scientific publishing be further improved? Eur Heart J 2012 (in press).
18. Saner H, Wood H. EJCPR is flourishing. Eur J Cardiovasc Prev Rehabil. 2006 ; 13: 1-2
19. Hamm CW, Bassand JP, Agewall S, et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: the Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2011 ; 32: 2999-3054
20. ESC Guidelines on the management of cardiovascular diseases during pregnancy: the Task Force on the Management of Cardiovascular Diseases during Pregnancy of the European Society of Cardiology (ESC). Eur Heart J. 2011 ; 32: 3147-3197
21. Tendera M, Aboyans V, Bartelink M-L, et al. ESC guidelines on the diagnosis and treatment of peripheral artery diseases. Eur Heart J. 2011 ; 32: 2851-2906
22. Poldermans D, Bax JJ, Boersma E, et al. Guidelines for pre-operative cardiac risk assessment and perioperative cardiac management in non-cardiac surgery. Eur Heart J. 2009 ; 30: 2769-2812
23. Perk J, De Backer G, Gohlke H, et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J. 2012 ; 33: 1635-1701
24. Moscoso Costa F, Ferreira J, Aguiar C, et al. Impact of ESC/ACCF/AHA/WHF universal definition of myocardial infarction on mortality at 10 years. Eur Heart J. 2012 ; 33: 2544-2550
25. Vahanian A, Alfieri O, Andreotti F, et al. Guidelines on management of valvular heart disease. Eur Heart J. 2012 ; 33: 2451-2496
26. McMurray JJV, Adamopoulos S, Anker SD, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. Eur Heart J. 2012 ; 33: 1787-1847
27. Steg PG, James SK, Atar D, et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC). Eur Heart J. 2012 ; 33: 2569-2619
28. Camm AJ, Lip GY, De Caterina R, et al.; ESC Committee for Practice Guidelines (CPG). 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 2012 Aug 24.
29. De Backer G, Ambrosioni E, Borch-Johnsen K, et al. European Journal of Cardiovascular Prevention & Rehabilitation European guidelines on cardiovascular disease prevention in clinical practice: third joint task force of European and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of eight societies and by invited experts). Eur J Cardiovasc Prev Rehabil. 2003 ; 10: 1-10
30. Nallamothu B and Lüscher TF. Moving from impact to influence: measurement and the changing role of medical journals. Eur Heart J 2012 [Epub ahead of print].
31. Galiè N, Hoeper MM, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J. 2009 ; 30: 2493-2537
32. Moya A, Sutton R, Ammirati F, et al. Guidelines for the diagnosis and management of syncope. Eur Heart J. 2009 ; 30: 2631-2671
33. Habib G, Hoen B, Tornos P, et al. Guidelines on the prevention, diagnosis, and treatment of infective endocarditis and the Task Force on the Prevention, Diagnosis, and Treatment of Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) and the International Society of Chemotherapy (ISC) for Infection and Cancer. Eur Heart J. 2009 ; 30: 2369-2413
34. Focus issue on prevention. Eur Heart J 2012; 34. Issue 4.
35. Kromhout D, Yasuda S, Geleijnse JM, et al. Fish oil and omega-3 fatty acids in cardiovascular disease: do they really work?. Eur Heart J. 2012 ; 34: 436-444
36. Genser B, Solbernagel G, de Backer G, et al. Nutrition in cardiovascular disease: a systematic review and metanalysis. Eur Heart J. 2012 ; 34: 444-451
37. Held C, Iqbal R, Lear SA, et al. Physical activity levels, ownership of goods promoting sedentary behaviour and risk of myocardial infarction: results of the INTERHEART study. Eur Heart J. 2012 ; 34: 452-466
38. Healy GN, Matthews CE, Dunstan DW, et al. Sedentary time and cardio-metabolic biomarkers in US adults: NHANES 2003-2006. Eur Heart J. 2011 ; 32: 590-597
39. Corrado D, Schmied C, Basso C, et al. Risk of sports: do we need a pre-participation screening for competitive and leisure athletes?. Eur Heart J. 2011 ; 32: 934-944
40. Corrado D, Drezner J, Basso C, et al. Strategies for the prevention of sudden cardiac death during sports. Eur J Cardiovasc Prev Rehabil. 2011 ; 18: 197-208
41. Corrado D, Pelliccia A, Heidbuchel H, et al. Recommendations for interpretation of 12-led electrocardiogram in the athlete. Eur Heart J. 2010 ; 31: 243-259
42. Mosterd A, Senden JP, Engelfriet P. Preventing sudden cardiac death in athletes: finding the needle in the haystack or closing the barn door?. Eur J Cardiovasc Prev Rehabil. 2011 ; 18: 194-196
43. Mahabadi AA, Massaro JM, Rosito GA, et al. Association of pericardial fat, intrathoracic fat and visceral abdominal fat with cardiovascular disease burden: the Framingham Heart Study. Eur Heart J. 2009 ; 30: 850-856
44. Klingenberg R, Hansson GK. Treating inflammation in atherosclerotic cardiovascular disease: emerging therapies. Eur Heart J. 2009 ; 30: 2838-2844
45. Braunwald E. Creating controversy where none exists: the important role of C-reactive protein in the CARE, AFCAPS/TexCAPS, PROVE IT, REVERAL, A to Z, JUPITER, HEART PROTECTION and ASCOT trials. Eur Heart J. 2012 ; 33: 430-432
46. Sever PS, Poulter NR, Chang CL, et al. on behalf of the ASCOT Investigators Evaluation of C-reactive protein prior to and on-treatment as a predictor of benefit from atorvastatin: observations from the Anglo-Scandinavian Cardiac Outcomes Trial. Eur Heart J. 2012 ; 33: 486-494
47. Mehta NN, Azfar RS, Shin DB, et al. Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using general practice research database. Eur Heart J. 2010 ; 31: 1000-1006
48. Barter PJ, Caulfield M, Eriksson M, et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med. 2007 ; 357: 2109-2122
49. Simic B, Hermann M, Shaw SG, et al. Torcetrapib impairs endothelial function in hypertension. Eur Heart J. 2011 ; 33: 1615-1624
50. Vergeer M, Bots ML, van Leuven SI, et al. Cholesteryl ester transfer protein inhibitor torcetrapib and off-target toxicity: a pooled analysis of the rating atherosclerotic disease change by imaging with a new CETP inhibitor (RADIANCE) trials. Circulation. 2008 ; 118: 2515-2522
51. Voight BF, Peloso GM, Orho-Melander M, et al. Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet. 2012 ; 380: 572-580
52. Stein EA, Roth EM, Rhyne JM, et al. Safety and tolarability of dalcetrapib (RO4607381/JTT-705): results from a 48-week trial. Eur Heart J. 2010 ; 31: 480-488
53. Lüscher TF, Taddei S, Kaski J-C, et al. Vascular effects and safety of dalcetrapib in patients with or at risk of coronary heart disease: the dal-VESSEL randomized clinical trial. Eur Heart J. 2012 ; 33: 857-865
54. Rubinshtein R, Kuvin JT, Soffler M, et al. Assessment of endothelial function by non-invasive peripheral arterial tonometry predicts cardiovascular events. Eur Heart J. 2010 ; 31: 1142-1148
55. Landmesser U, von Eckardstein A, Kastelein J, et al. Increasing high-density lipoprotein cholesterol by cholesteryl ester transfer protein-inhibition: a rocky road and lessons learned? The early demise of the dal-HEART programme. Eur Heart J. 2012 ; 33: 1712-1715
56. Chapman MJ, Le Goff W, Guerin M, et al. CETP-at the heart of the action of lipid-modulating therapy with statins, niacin and CETP inhibitors. Eur Heart J. 2010 ; 31: 149-164
57. Chapman MJ, Ginsberg HN, Amarenco P, et al. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Eur Heart J. 2011 ; 32: 1345-1361
58. 12 are predictors of CHD mortality in older adults. Eur J Cardiovasc Prev Rehabil 2011 [Epub ahead of print].
59. Antoniades C, Antonopoulos AS, Tousoulis D, et al. Homocysteine and coronary atherosclerosis. From folate fortification to the recent clinical trials. Eur Heart J. 2009 ; 30: 6-15
60. Cappuccio FP, Cooper D, D'Elia L, et al. Sleep duration predicts cardiovascular outcomes: a systematic review and meta-analysis of prospective studies. Eur Heart J. 2011 ; 32: 1484-1492
61. Grobbee DE. The era of preventive cardiology. Eur J Prev Cardiol. 2012 ; 19: 3-4
62. Browne JL, Grobbee DE. Cardiovascular prevention and international health: time for action. Eur J Cardiovasc Prev Rehabil. 2011 ; 18: 547-549
63. Dieren S, van, Beulens JWJ, Schouw van der YT, et al. The global burden of diabetes and its complications: an emerging pandemic. Eur J Cardiovasc Prev Rehabil. 2010 ; 17: 3-8
64. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012): the Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur J Prev Cardiol. 2012 ; 19: 585-667
65. Vanhees L, Geladas N, Hansen D, et al. on behalf of the writing group. Eur J Prev Cardiol. 2012 ; 19: 1005-1033
66. Jiang J, Hong T, Ronghui Y, et al. Knowledge of secondary prevention guidelines for coronary heart disease: results from a physicians' survey in China. Eur J Prev Cardiol. 2012 ; 19: 991-998
67. Ambrosio G, Steinhubl S, Gresele P, et al. Impact of chronic antiplatelet therapy before hospitalization on ischemic and bleeding events in invasively managed patients with acute coronary syndromes: the ACUITY trial. Eur J Cardiovasc Prev Rehabil. 2011 ; 18: 121-128
68. Cavender MA, Nicholls SJ, Lincoff AM. Strategies for the development of new PPAR agonists in diabetes. Eur J Cardiovasc Prev Rehabil. 2010 ; 17 (Suppl 1). 32-37
69. Zannad F, Koenig W. Risk-guided therapy: a first step to personalized medicine. Eur J Prev Cardiol. 2012 ; 19 (Suppl 2). 5-6
70. Thom S, Field J, Poulter N, et al. Use of a Multidrug Pill In Reducing cardiovascular Events (UMPIRE): rationale and design of a randomised controlled trial of a cardiovascular preventive polypill-based strategy in India and Europe. Eur J Prev Cardiol 2012 [Epub ahead of print].
71. Kotseva K, Wood D, De Backer G, et al. EUROASPIRE III: a survey on the life style, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries. Eur J Cardiovasc Prev Rehabil. 2009 ; 16: 121-137
72. Kotseva K, Wood D, De Backer G, et al. EUROASPIRE III. Management of cardiovascular risk factors in asymptomatic high-risk patients in general practice: cross-sectional survey in 12 countries. Eur J Cardiovasc Prev Rehabil. 2010 ; 17: 530-540
73. Piepoli MF, Corra U, Benzer W, et al. Secondary prevention through cardiac rehabilitation: from knowledge to implementation. A position paper from the Cardiac Rehabilitation Section of the European Association of Cardiovascular Prevention and Rehabilitation. Eur J Cardiovasc Prev Rehabil. 2010 ; 17: 1-17
74. Neubeck L, Redfern J, Fernandez R, et al. Telehealth interventions for secondary prevention of coronray heart disease: a systematic review. Eur J Cardiovasc Prev Rehabil. 2009 ; 16: 281-289
75. Mezzani A, Agostoni P, Cohen-Solal A, et al. Standards for the use of cardiopulmonary exercise testing for the functional evaluation of cardiac patients: a report from the Exercise Physiology Section of the European Association of Cardiovascular Prevention and Rehabilitation. Eur J Cardiovasc Prev Rehabil. 2009 ; 16: 249-267
76. Warren JM, Ekelund U, Besson H, et al. Assessment of physical activity - a review of methodologies with reference to epidemiological research: a report by the Exercise Physiology Section of the European Association of Cardiovascular Prevention and Rehabilitation. Eur J Cardiovasc Prev Rehabil. 2010 ; 17: 127-139
77. Metsios GS, Stavropoulos-Kalinoglou A, Panoulas VF, et al. Association of physically inactivity with increased cardiovascular risk in patients with rheumatoid arthritis. Eur J Cardiovasc Prev Rehabil. 2009 ; 16: 188-194
78. Cooney MT, Dudina A, De Bacquer D, et al. How much HDL cholesterol add to risk estimation? A report from the SCORE investigators. Eur J Cardiovasc Prev Rehabil. 2009 ; 16: 304-314
79. Eriksson M, Zethelius B, Eeg-Olofsson K, et al. Blood lipids in 75,048 type 2 diabetic patients: a population-based survey from the Swedish National diabetes register. Eur J Cardiovasc Prev Rehabil. 2011 ; 18: 97-105
80. Van Dieren S, Beulens JW, van der Schouw YT, et al. The global burden of diabetes and its complications: an emerging pandemic. Eur J Cardiovasc Prev Rehabil. 2010 ; 17 (Suppl 1). S3 - S8
81. Friis-Moller N, Thiebaut R, Reiss P, et al. Predicting the risk of cardiovascular disease in HIV-infected patients: the data collection on adverse effects of anti-HIV drugs study. Eur J Cardiovasc Prev Rehabil. 2010 ; 17: 491-501